Want to join the conversation?
$ESRX's PBM gross profit for 3Q15 rose by 4.7% from last year. This increase is due to better management of ingredient costs and formulary, as well as cost savings from rise in aggregate generic fill rate. Additionally, this increase is due to $45.2MM of transaction and integration costs for 3Q15, down from $65MM in 3Q14.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)